153 results about "Neutralization" patented technology

The present application relates generally to the field of biochemical detection. The invention provides a method and a kit for detecting an anti-IgE antibody in a biological sample. The method for detecting the anti-IgE antibody in the biological sample comprises the following steps: (a) contacting the biological sample with an acidolysis solution to dissociate the anti-IgE antibody from IgE so as to obtain an acidolysis sample; (b) contacting the acidolysis sample with a neutralization buffer solution to terminate acidolysis so as to obtain a to-be-detected sample; and (c) determining the anti-IgE antibody in the sample to be detected. The kit for detecting the anti-IgE antibody in the biological sample comprises an acidolysis solution and a neutralization buffer solution. The problem of background IgE interference in anti-IgE antibody detection is solved to a certain extent.

The invention discloses an anti-respiratory syncytial virus antibody and application thereof. The anti-respiratory syncytial virus antibody or the antigen binding fragment thereof can specifically recognize the pre-F protein of the respiratory syncytial virus and neutralize the respiratory syncytial virus, especially has efficient neutralizing activity on an A2 strain of the respiratory syncytial virus, can effectively prevent and control infection of the respiratory syncytial virus, and can be used for preparing the anti-respiratory syncytial virus antibody or the antigen binding fragment thereof. A new thought is provided for detection of the respiratory syncytial virus and prevention and treatment of diseases related to respiratory syncytial virus infection, and wide application prospects are achieved.

The application discloses a high-expression-based CRM197 protein specific neutralization detection method and belongs to the technical field of biological detection. The method comprises the following steps: S1, strain resuspension: Corynebacterium diphtheriae is resuspended to obtain a bacterial suspension; S2, bacterial liquid culture: the bacterial suspension is inoculated into an iron trichloride YC liquid culture medium to be cultured to obtain a bacterial liquid; and S3, specific neutralization: the bacterial liquid is inoculated on Elek's medium to be subjected to virulence determination. The application establishes a novel CRM197 protein specific neutralization detection method, greatly improves the technical requirements of detection effect and time limit, and provides a novel detection method for biological science.

This invention provides a human antibody with neutralizing ability against the JN.1 variant of SARS-CoV-2 and its application, belonging to the field of biomedical technology. The antibody comprises a heavy chain sequence as shown in SEQ ID NO:1 and a light chain sequence as shown in SEQ ID NO:2; or comprises a heavy chain sequence as shown in SEQ ID NO:3 and a light chain sequence as shown in SEQ ID NO:4. The antibody of this invention binds to the extracellular domain of the JN.1 variant spike protein via ECG. 50 The value was significantly lower than that of its parent antibody, with a binding capacity increase of 3 to 5 times or more. In the pseudovirus neutralization experiment, the antibody showed a half-maximal neutralizing concentration (IC50) against JN.1 pseudovirus. 50 The antibody also showed significantly better performance than the parent antibody, with a neutralizing activity increase of 3 to 24 times or more. Furthermore, the antibody's melting temperature exceeded 75°C, demonstrating good thermal stability.

The invention discloses a neutralizing swine monoclonal antibody pO18-40 and a neutralizing swine monoclonal antibody pO18-43 for foot and mouth disease virus type O. The amino acid sequences of a heavy chain variable region (VH) and a light chain variable region (VL) of the antibody pO18-40 are respectively as shown in SEQ ID No. 1 and SEQ ID No. 2; the amino acid sequences of VH and VL of the antibody pO18-43 are respectively as shown in SEQ ID No. 3 and SEQ ID No. 4. The antibody obtained by the invention is a full-swine-source antibody, can specifically neutralize the classical strain of the O-type foot-and-mouth disease virus, and can clearly distinguish the classical strain of the O / Cathay topological type from the variant strain of the O / Cathay topological type. A key antigen epitope recognized by the antibody is located at the 149th amino acid of a VP1 protein G-H ring, and the site is a key site of O / Cathay strain antigen variation and vaccine immune protection. The antibody provided by the invention provides an important tool and theoretical basis for serological detection of O-type FMDV, vaccine immune effect evaluation and optimal design of broad-spectrum vaccines.

A single-domain antibody (sdAb) which binds to head domain of VP6 derived from a human rotavirus A and has neutralization activity against different the rotavirus A types.

The application discloses camel-derived nanobodies of feline calicivirus and application thereof, and belongs to the field of biological medicine. The application takes feline calicivirus as an immunogen, and through steps of immunizing a camel, constructing a library, enriching sequencing and the like, two nanobodies VHH-V14 and VHH-V29 are screened, and the amino acid sequences of the two nanobodies are shown as SEQ ID NO. 1-2. Experimental results show that the nanobodies VHH-V14 and VHH-V29 are nanobodies with outstanding neutralization activity to feline calicivirus, and the IC 50 of the two nanobodies is 0.6536 mg / mL and 0.6931 mg / mL respectively, and the two nanobodies have good inhibiting effect on feline calicivirus. The application provides new biological materials for prevention and treatment of feline calicivirus infection, and provides new design theory and technical support for antibody treatment strategy of feline calicivirus, and has outstanding significance for clinical treatment of feline calicivirus infection.

The application discloses a recombinant nanobody against swine influenza virus of H1N1 subtype, and a preparation method and application thereof, and belongs to the field of biological medicines. A VHH sequence of the nanobody against swine influenza virus of H1N1 subtype is screened from a nanobody bacterial library of an immunized llama, the VHH sequence is directionally cloned into a pPIC9K vector to construct a recombinant eukaryotic expression plasmid, and the recombinant eukaryotic expression plasmid is transformed into a Pichia pastoris expression system to screen an expression engineering strain, and the recombinant nanobody is obtained after induction culture of the expression engineering strain. It is proved by in-vitro and in-vivo experiments that the recombinant nanobody developed in the application can neutralize CA / 04 and has a remarkable therapeutic effect. Therefore, the neutralizing nanobody provided in the application has considerable potential in treating CA / 04. The findings will provide experimental data for developing nanobody preparations against swine influenza virus of H1 subtype and provide a new strategy for preventing and controlling swine influenza.

The invention relates to the technical field of biology, and aims to provide an M13 recombinant bacteriophage with PRRSV broad-spectrum neutralizing activity for displaying NPC and application of the M13 recombinant bacteriophage. A nano antibody-CD163 peptide fragment conjugate NPC shown as SEQ ID NO: 1 is displayed on the surface of the N end of capsid protein III of the M13 recombinant phage, 1-3 NPC molecules are contained on the surface of each phage particle, and the phage is used for neutralizing PRRSV (Porcine Reproductive and Respiratory Syndrome Virus). The recombinant bacteriophage provided by the invention is easy to prepare, extremely high in virus titer and excellent in thermal and pH stability; in Marc-145 and PAMs cells, the compound shows strong neutralizing activity on PRRSV II type 1, 3, 5 and 8 pedigree, so that the compound has broad-spectrum neutralizing capacity; the compound can be used as a PRRSV prevention and control preparation, and a new thought is provided for development of safe and efficient novel antiviral drugs or biological preparations.

The sampling equipment comprises an adapter base, connecting bases are connected to the two ends of the adapter base, a neutralizing pipe is connected to one end of the adapter base, a neutralizing assembly is arranged in the neutralizing pipe, the neutralizing assembly comprises a rotating disc rotationally clamped in the neutralizing pipe, a side block is connected to the outer side of the rotating disc, and a first sliding groove is formed in the outer side of the neutralizing pipe; the side blocks are slidably clamped in the first sliding grooves, and the bottom end of the neutralizing pipe is connected with a fixing pipe. The arranged neutralization assembly can neutralize antibiotics in a blood sample of a patient before formal sampling is started, the inhibition effect of emergency antibiotic injection on germs in the blood sample of the patient is reduced as much as possible by neutralizing the antibiotics in the blood of the patient, and when the device is used, the concentration of the antibiotics in the blood of the patient is detected firstly; then sampling liquid is guided into the flow guide assembly through the liquid inlet hole, the flow guide assembly can guide the liquid into the neutralizing pipe, and the antibiotics are neutralized or absorbed through the neutralizing agent coated on the side wall of the connecting hole.

This invention belongs to the field of genetic engineering. By introducing a TC tag between amino acids 199 and 200 of the wild-type bluetongue virus non-structural protein NS2, a recombinant virus was rescued. Analysis of viral plaques and growth curves revealed that the recombinant virus formed plaques of similar size to the wild-type virus, and their growth curves showed no significant difference. Immunofluorescence and FlasH-EDT2 staining of NS2 showed that the fluorescence of NS2 labeled with anti-NS2 antibody overlapped with that labeled with FlasH-EDT2. Three-dimensional imaging of FlasH-EDT2-labeled NS2 revealed that the viral inclusion bodies exhibited fluorescence around the periphery but no fluorescence inside, displaying an overall "core-shell" hierarchical structure. This recombinant bluetongue virus can be used for tracing and localizing NS2 protein and viral inclusion bodies in living cells, and can also be applied to BTV neutralization assays, antiviral drug screening, and other related research.

The invention relates to the field of chemical analysis and detection, in particular to a method for rapidly detecting the concentration of industrial concentrated acid based on neutralization reaction, which comprises the following steps: 1, theoretical calculation; converting molar concentration according to acid density and mass fraction; 2, accurately measuring the volume of target acid by using a pipette; 2, injecting 100-150ml of pure water into the triangular flask, and adding 3-5 drops of phenolphthalein; 3, slowly injecting an acid sample into the triangular flask, and slightly shaking and uniformly mixing; 4, adding 10.00 ml of NaOH solution by using the pipette, and oscillating for 10-20 seconds; 3, result interpretation: transparency and colorless: acid is excessive when the acid concentration reaches the standard, pH is less than or equal to 8.2 after neutralization, pink lasts for 20-30 seconds, and reinspection is needed when the acid concentration is insufficient and the pH is greater than or equal to 8.3. The method has the beneficial effects that 1, a reverse judgment method is adopted, namely the conventional end-point titration is replaced by fixed alkali amount, so that the detection time is shortened to 2 minutes; 2, safety design: pre-dilution reduces the risk of acid mist, and only a trace amount of raw acid is needed to avoid acid corrosion; 3, multi-acid adaptation: compatibility with detection of different types of concentrated acids is realized through pipetting volume adjustment;

The invention relates to the technical field of protein detection, in particular to a detection method and a kit for detecting an anti-Nephrin antibody. The detection method comprises the following steps: capturing an anti-Nephrin antibody in a sample to be detected on an SA matrix by adopting biotinylated Nephrin protein to obtain a first compound; carrying out acidolysis desorption and neutralization on the first compound, and directionally fixing an antibody by Protein G to obtain a second compound; aiming at the second compound, detecting by adopting a biotin-streptavidin-HRP (Horse Radical Polymorphism) system; the acidolysis desorption comprises the following steps: treating the first compound for 10-20 minutes by adopting an acid solution with the pH value of 2-3 under the conditions that the temperature is 35-40 DEG C and the speed is 500-800 rpm. The method provided by the invention can accurately and quickly detect the level of the anti-Nephrin antibody in the sample, and has important application value.

The invention relates to the field of antibody engineering, in particular to a monoclonal antibody specifically targeting a monkey pox virus and application of the monoclonal antibody. According to the invention, by screening mouse memory B cells specifically combined with monkey pox virus envelope protein A35R, monkey pox virus antibodies 1H4, 3H3, 3H6, 13H1 and 17H1 with high neutralization activity are obtained. Wherein 17H1 has excellent affinity and neutralizing efficacy on monkey pox virus and has a strong in-vivo protection effect, and 100% of survival rate of challenged mice is achieved in prevention and treatment experiments. The sequence of the antibody is completely different from that of an existing monkey pox virus antibody, and a new candidate product is provided for detection, diagnosis, prevention and treatment of the monkey pox virus.

The invention provides a GP4 protein antigen epitope peptide of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) and a monoclonal antibody, and provides a hybridoma cell strain for generating the monoclonal antibody, and the preservation number of the hybridoma cell strain is CCTCC (China Center for Type Culture Collection) NO.C2025259. The monoclonal antibody provided by the invention does not react with various other swine viruses such as PCV2, PEDV, GETV and the like, and has good specificity; the polypeptide has good affinity with PRRSV structural protein GP4 at the molecular level and the cellular level, and epitope information is clear. The antibody can significantly inhibit the infection efficiency of a PRRSV-2 JXwn06 strain in MARC-145 cells and alveolar macrophages, has a good PRRSV in-vitro neutralization effect, can be used for developing a high-specificity PRRSV-2 GP4 detection reagent, and is expected to be used as a candidate drug for passive immune prevention and treatment of PRRS.

The application discloses a human monoclonal antibody for neutralizing SARS-CoV-2 and application thereof, wherein the amino acid sequences of CDR-H1, CDR-H2 and CDR-H3 in the heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6, the amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 in the light chain variable region are respectively shown as SEQ ID NO:11, GKN and SEQ ID NO:15, the monoclonal antibody has strong neutralization activity on SARS-CoV-2, lays a foundation for diagnosis, treatment and development of related drugs of SARS-CoV-2 infection related diseases, and has a good application prospect.

The application provides a target RBD anti-Omicron fully human monoclonal antibody 9C4 and application thereof, and belongs to the technical field of microbiology and immunology. The monoclonal antibody 9C4 comprises a heavy chain variable region and a light chain variable region, the amino acid sequences of three complementarity determining regions of the heavy chain variable region are GYAFTTYG, ISTYNGNT and ATSLGLWFGQNS respectively, and the amino acid sequences of three complementarity determining regions of the light chain variable region are SGSIASNY, EDN and QTYDGSNQV respectively. The monoclonal antibody 9C4 provided by the application has high-efficiency, specific anti-Omicron neutralization activity, is fully human, has good stability, and has great application potential in the preparation of a novel coronavirus detection product or a drug for preventing and treating a novel coronavirus disease.

Provided is an immunochromatographic method with high detection sensitivity. An immunochromatographic method includes: a mixing step of obtaining a mixture containing a magnetic particle complex by mixing a sample that can contain an antigen and a magnetic particle modified with a substance having specific affinity for the antigen; a capturing step of capturing the magnetic particle; a dissociation step of obtaining an antigen concentrate by mixing the captured magnetic particle and a dissociation solution in an amount smaller than the sample that can contain the antigen, and dissociating the modified magnetic particle; a neutralization step of obtaining a neutralized antigen concentrate; a development step of developing on an insoluble carrier having a reaction site on which a second binding substance is immobilized, in a state in which a gold particle complex is formed as a complex of the antigen in the neutralized antigen concentrate and a gold particle modified with a first binding substance; a capturing step of capturing the gold particle complex on the reaction site; and a silver amplification step of performing silver amplification on the gold particle complex.

The present application relates to the technical field of biotechnology, in particular to a monoclonal antibody against A29L protein of monkeypox virus and application thereof. The present application prepares the monoclonal antibody against A29L protein of monkeypox virus, and through optimization of antibody screening and expression technology, the antibody with high affinity and high specificity is screened, and then a new tool is provided for rapid detection, effective neutralization and treatment of monkeypox virus, and an important immunological basis is provided for vaccine research and development and treatment scheme design of monkeypox virus.

The invention discloses an F1 monoclonal antibody and application thereof, the F1 monoclonal antibody is used for specifically binding a 6HB structural domain in a spike protein S2 subunit of SARS-CoV-2, the F1 monoclonal antibody comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of the VHCDR1, the VHCDR2 and the VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of the VLCDR1, the VLCDR2 and the VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses an application of the F1 monoclonal antibody. The F1 monoclonal antibody can neutralize SARS-CoV-2 virus infection, and has important application value in serological detection of new coronavirus, preparation of a reagent for new coronavirus infection detection and a reagent for new coronavirus antigen or antibody detection.

The application discloses a neutralizing antibody P36-5D2 for neutralizing SARS-CoV-2 in a broad spectrum and application thereof. The application provides an IgG antibody, named antibody P36-5D2, which is composed of a light chain and a heavy chain; CDR1, CDR2 and CDR3 in the heavy chain variable region are in sequence 4 from N-terminal 45-52th, 70-77th and 116-130th amino acid residues; CDR1, CDR2 and CDR3 in the light chain variable region are in sequence 6 from N-terminal 46-51th, 69-71th and 108-116th amino acid residues. The antibody P36-5D2 has the effect of neutralizing SARS-CoV-2 in a broad spectrum, and has strong neutralization capacity to wild-type novel coronavirus and natural mutant strains. The application has great application value for prevention and control of the novel coronavirus, and will have far-reaching social significance.

The application discloses a single-domain antibody against African swine fever virus E165R protein and a screening method and application thereof, relates to the technical field of bioengineering, and provides the single-domain antibody against African swine fever virus E165R protein and a specific amino acid sequence, a gene coding the single-domain antibody, an expression vector comprising the gene and a bacteriophage expressing the gene, and applies the single-domain antibody against African swine fever virus E165R protein to immunological detection of African swine fever virus. The single-domain antibody provided by the application has strong specificity, high sensitivity and strong neutralization activity, and can be used in daily immunological detection of epidemic diseases and future system construction for prevention and control of epidemic diseases.

The application relates to the field of biomedical technology, in particular to a monoclonal antibody specifically combined with EsxA and a therapeutic reagent; the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementarity determining regions VLCDR1, VLCDR2 and VLCDR3, the heavy chain variable region comprises three complementarity determining regions VHCDR1, VHCDR2 and VHCDR3, the light chain variable region is an amino acid sequence identical to SEQ.ID.NO.1 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%, and the heavy chain variable region is an amino acid sequence identical to SEQ.ID.NO.2 at least 90%, 95%, 96%, 97%, 98%, 99% or 100%; the therapeutic reagent comprises the monoclonal antibody, a single-chain antibody, a human-mouse chimeric antibody or a humanized antibody; the monoclonal antibody provided by the application is high in specificity, neutralization activity and protective power and is directed to EsxA, has the characteristics of mediating complement-dependent cytotoxicity, is excellent in in-vivo antibacterial activity and can support the construction of an anti-EsxA chimeric or humanized genetically engineered antibody with neutralization activity.

The disclosures of the invention arc directed to the manufacture of effective, affordable vaccines that arc globally accessible. Using a platform conjugation technology, highly immunogenic conjugate vaccines were produced that elicit broad cross-neutralization to variants of concern (VOC), manufactured cheaply compared to mRNA vaccines. Protein-protein conjugates and Toll-Like Receptor (TLR) agonist adjuvants were shown to enhance immunogenicity and induce broad cross-protection against VOC, a characteristic lacking in early mRNA CO VID-19 vaccines. Murine nAb titers from Beta-only conjugates were equivalent between Beta, Delta, Omicron BA.l, BA.2, and BA.4 / BA.5, which were circulating up to three years after the antigenic strain. Additionally, Beta-Delta bivalent conjugate vaccines readily prevented disease in hamster challenge, which demonstrates a vaccine with remarkably broad cross-protection and potential to protect for extended periods despite mutations, without requiring expensive boosters or antigen adaption. This vaccine can be produced in our highly automated, large-scale manufacturing facility enabling economical production of inexpensive, effective vaccines for high-need areas.

The application discloses a screening method of raw blood plasma containing high-titer anti-HCMV neutralizing antibodies and a detection method of anti-HCMV neutralizing antibody titer, and belongs to the technical field of blood products. The screening method and the detection method provided by the application are both based on a fluorescence immunodot test, and the fluorescence immunodot test is performed on a HCMV virus diluent which can be exactly neutralized by anti-HCMV immunoglobulin national standard containing a known amount of anti-HCMV neutralizing antibodies and a to-be-detected blood plasma sample diluted according to a determined multiple or a to-be-detected sample diluted in a series of gradients. The method provided by the application can obtain a result in about 48 hours, and the result data is collected and analyzed by an immunodot analyzer, without naked-eye observation, so that the determination of the result is more objective and accurate.

The application relates to the field of biological medicine, and provides a tetravalent antibody for neutralization of a novel coronavirus, which comprises an antibody monomer nAb and an scFv structure coupled at the Fc end of the heavy chain of the antibody monomer through a linker 1. Compared with the nAb antibody, the tetravalent antibody has higher antiviral capacity for various epidemic strains of the novel coronavirus, and has good application value.

The invention discloses an anti-rabies virus G protein nano antibody and application thereof, and belongs to the technical field of nano antibodies. The nano antibody is an antibody 11G6, an antibody 9F7 or an antibody 9A3; the amino acid sequence of the antibody 11G6 is as shown in SEQ ID NO. 8; the amino acid sequence of the antibody 9F7 is as shown in SEQ ID NO. 13; the amino acid sequence of the antibody 9A3 is as shown in SEQ ID NO. 18. According to the invention, the nano antibody with high affinity and high neutralizing activity is screened by a phage display technology. On the basis, the advantage that the size of the nano antibody is small is utilized, the unique ability of the nano antibody to penetrate through the BBB is verified through a Transwell experiment, and the defect that macromolecules such as antibodies and drugs cannot penetrate through the BBB to enter the brain is overcome. The invention provides a new drug choice for the treatment of rabies virus, and has important clinical significance.

Disclosed herein are antibodies that bind to PD-1, comprising one or more CDRs selected from the amino acid sequences of SEQ ID NOs: 13, 14, 15, 16, 17, and 18. The antibodies have high affinity and low dissociation rate for PD-1, as well as the activity for neutralizing PD-1 in vitro. The antibodies disclosed herein can be full-length antibodies or antigen-binding fragments thereof. The antibodies can be used for detecting PD-1 and the like.

The invention discloses a recombinant nano antibody for resisting H1N1 subtype A swine influenza virus as well as a preparation method and application thereof, and belongs to the field of biological medicines. The preparation method comprises the following steps: screening a VHH sequence for resisting an A H1N1 subtype swine influenza virus from a nano antibody bacterial library of an immune alpaca, directionally cloning the VHH sequence into a pPIC9K vector to construct a recombinant eukaryotic expression plasmid, transforming the recombinant eukaryotic expression plasmid into a pichia pastoris expression system to screen and express an engineering strain, and carrying out induced culture on the engineering strain to obtain the recombinant nano antibody. In-vitro and in-vivo experiments prove that the recombinant nano antibody developed by the invention can neutralize CA / 04 and shows a remarkable treatment effect. Therefore, the neutralizing nano antibody provided by the invention has great potential in the aspect of treatment of CA / 04. The discovery provides test data for research and development of anti-H1 subtype swine influenza virus nano antibody preparations, and provides a new strategy for prevention and control of swine influenza.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).